1 / 6

RAC US Exam Questions

Now you can pass the RAC US exam by the help of Certs4you dumps and braindumps. Certs4you provide you 100% approved questions along with latest test engine which helps you to better study and enhance your learning skills. Certs4you leading brand in education industry. For more information and latest RAC US Braidnumps visi us here. <br>http://www.certs4you.com/raps/rac-us-dumps.html<br>

certsyou_4
Télécharger la présentation

RAC US Exam Questions

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 100% REAL EXAM QUESTIONSANSWERS Buy Complete Questions Answers Filefrom http://www.certs4you.com/raps/rac-us-dumps.html

  2. The Food and Drug Administration Modernization Act (FDAMA) established two types of formal early collaboration meetings. Which of the following is one of thosemeetings? PDPmeeting AgreementMeeting Pre-IDEmeeting Type Ameeting Answer:B A sponsor intends to submit a Special Protocol Assessment (SPA) request for a clinical trial that will form the primary basis of an efficacy claim in an NDA. Which of thefollowing is TRUE? The sponsor should submit the SPA request within 30 days following the start of the trial to expedite FDAfeedback An SPA provides an opportunity to focus on general drug developmentissues The SPA request will be handled as a request for a Type B meeting A sponsor can submit a revised protocol while the agency is reviewing an earlier version of the sameprotocol Answer:D Devices that are exempt from premarket notificationare: All Class Idevices Some Class Idevices Most Class I devices and some Class IIdevices All Class I devices and some Class II devices Answer:C

  3. Your company wishes to seek approval of a combination of individually approved anti- hypertensive and anti-diabetic drugs. However, there is no Reference Listed Drug (RLD) for the proposed combination. Which of the following regulatory pathways is mostapplicable? A. 505(b)(2) B. 510(k) C. 505(b)(1) D. 505(j) Answer:A The following applies to autologous chondrocytes expanded in vitro for the repair of cartilage defects: Regulated under Section 351 of the Public Health Service Act and no premarket approval required Regulated under Section 351 of the Public Health Service Act and premarket approval required Regulated under Section 361 of the Public Health Service Act and no premarket approval required Regulated under Section 361 of the Public Health Service Act and premarket approval required Answer:B Which of the following is the best regulatory pathway for drugs containing similar active ingredients as a previously approved drug for a newindication? A. 505(j) ANDA B. 505(b)(1) NDA C. 505(b)(2)NDA D. 505 (d) Substantial Evidence ofEffectiveness Answer:C

  4. In order to be approved by FDA, a generic drug must be therapeutically equivalent to the branded product with the exceptionof: DosageForm Route ofAdministration InactiveIngredient(s) Labeling Answer:C Your company is developing a New Chemical Entity (NCE) drug to treat Glioblastoma multiforme, which is the deadliest and most common form of malignant brain tumor. The compound team has designed a pivotal study protocol with a clinically meaningful andwell- established primary endpoint. To increase the likelihood FDA will agree with thestudy design, which of the following regulatory strategies has to occur prior to initiating the pivotalstudy? Request Fast Trackdesignation Request priorityreview Request approval under Subpart H, Accelerated Approval of New Drugs for Serious or Life ThreateningIllness Request Special ProtocolAssessment Answer:D Which federal law made it illegal for physicians being reimbursed by federally funded programs to prescribe or recommend that the patient use a particular manufacturer's medical products when the doctor receives payment from thatmanufacturer? Medicare and Medicaid Patient Protection Act of1987 Food, Drug, and Cosmetic Act of 1938 (FD&C Act) Food and Drug Administration Modernization Act of 1997(FDAMA) Food and Drug Administration Amendments Act of 2007(FDAAA) Answer:A

  5. Company Z selected a proprietary name for its new molecular entity, currently in development. The NDA will be submitted in six months. All of the following are Relevant to the proprietary nameEXCEPT: The request for proprietary name approval may be submitted with the NDA. The proprietary name submission package may be Submitted up to one month after NDAsubmission. The request for proprietary name approval may be submitted prior to the NDA. FDA will communicate to the applicant a tentative acceptance or non-acceptance of the proposed proprietary name submitted with the NDA within 90 days of the receipt of the completesubmission. Answer:B • WHY CHOOSEUS? • RAC-US exam QuestionsAnswers • CERTS4YOU RAPS RAC-US PDF and TestEngine • RAPS RAC-US 100% accurateanswers • Up-to-date Array RAPS Certified Examinerdumps • RAC-US has Multiple Choice, Hot-Spot and Drag Drop and all other type of ExamQuestions. • All RAPS RAC-US questions are verified by our expert’sengineers. • We offer Free RAPS RAC-US Demo. Please contact support to getit.

  6. http://www.certs4you.com/raps/rac-us-dumps.html

More Related